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ABSTRACT 
 
OBJECTIVE: The objective of this selective Evidence Based Medicine review is to determine 
whether or not Horse Antithymocyte Globulin (ATG) plus Cyclosporine (CsA) is the most 
effective first-line therapy for patients with bone marrow failure disorders.  
 
STUDY DESIGN: Review of two randomized control trials (RCTs) and one single-center 
retrospective study, which were published between 2010 and 2013. All studies were published in 
the English language.  
 
DATA SOURCES: Two randomized control trials and one single-center retrospective study 
published in peer-reviewed journals, which were found using PubMed.  
 
OUTCOMES MEASURED: Each of the three trials measured the patient-oriented outcome of 
overall survival. Shin et al also assessed failure free survival. Survival was measured at different 
year markers after therapy between all three studies and also implemented the use of the Kaplan 
Meier curve for overall survival. 
 
RESULTS: Scheinberg et al (2011) was the only study which yielded statistically significant 
data supporting Horse ATG plus CsA as the superior therapy for patients with bone marrow 
failure disorders (p-value = 0.04). Both the Passweg et al (2010) and Shin et al (2013) studies 
demonstrated inconclusive data, as the results in each study did not yield a statistically 
significant difference between the three treatment modalities: Horse ATG plus CsA, Rabbit ATG 
plus CsA, or Basic Supportive Care (BSC). 
 
CONCLUSIONS: Results were inconclusive due to only one of the three studies demonstrating 
data to support Horse Antithymocyte Globulin as the best initial treatment for patients with bone 
marrow failure disorders.  
 
KEY WORDS: Aplastic Anemia, Myelodysplastic Syndrome, Anti-Thymocyte Globulin, 
Cyclosporine  
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INTRODUCTION 
Bone marrow failure disorders are acquired or inherited rare diseases in which one or all 
cell lines of the bone marrow are affected: it fails to produce a sufficient supply of red blood 
cells, white blood cells, and/or platelets.1 It is estimated that Aplastic Anemia affects 4 out of 1 
million people in the United States per year, whereas Myelodysplastic syndromes affect more 
than 15,000 people in the United States per year.1 There is no readily available data which 
describes the annual healthcare costs nor annual healthcare visits for patients with these 
conditions. However, a variety of factors influence these costs and healthcare visits because of 
the very unique patient population. Factors that influence the number of healthcare visits include 
out-patient clinic visits/follow-up appointments, emergency room visits, spontaneous hospital 
admissions, and a patient’s comorbid conditions.2 With that being said, it is also difficult to 
delineate an average price for the amount of care that goes into these patients. However, the 
following studies in this selective Evidence Based Medicine review demonstrate one treatment 
route in which costs are completely covered: clinical trials.    
Although most cases of Aplastic Anemia and MDS are idiopathic, there are some theories 
as to what may trigger or cause these conditions: chemotherapy, radiation therapy, benzene or 
other toxic chemicals, and certain viral infections.1 Diagnosing these conditions is difficult 
because the symptom presentation is so broad and may resemble other more benign illnesses. 
Common symptomatology is due to a deficit in one or more of the blood cell lines. Red blood 
cells (RBCs) are responsible for transporting oxygen throughout the body. A deficiency in RBCs 
would produce symptoms including fatigue, weakness, pallor, and dyspnea. A deficiency in 
platelets, which are responsible for clotting blood, may produce symptoms such as unexplained 
bleeding/bruising and petechiae. White blood cells play a significant role with helping the body 
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fight infection and foreign invaders; therefore, a deficit in these cells could cause fevers and/or 
frequent infections.1,3 
Treatment for both Aplastic Anemia and MDS depends on a variety of factors including 
age of the patient, the patient’s general well-being, and the severity of the patient’s disease. One 
option for patients with more mild forms of their disease is supportive care. The purpose of 
supportive care is to help with the management of symptomatology to help with improvement in 
quality of life; this includes blood transfusions and growth factor therapy. Immunosuppressive 
therapy is another treatment modality which is reserved for patients with moderate to severe 
disease who necessitate medicinal intervention. This includes polyclonal antibody therapy such 
as Antithymocyte Globulin or oral immunosuppressants such as Cyclosporine or Mycophenolate 
Mofetil. Chemotherapy and radiation is also an option, which can help with the destruction or 
complete cessation of division of immature/defective blood cells. Finally, the gold standard 
treatment for any bone marrow failure disorder is blood and bone marrow stem cell 
transplantation to replace the damaged blood cell lines in the bone marrow.1 However, many 
patients do not qualify for this treatment modality due to not having an adequately matched 
donor or having their condition be too poor to tolerate the long process of a transplant. 
Currently, there is no known or proven immunosuppressive cure for bone marrow failure 
disorders, especially for those who cannot feasibly receive transportation, which is the only 
know cure for these diseases;4 however the aforementioned treatment methods have helped to 
improve symptoms, quality of life, and have prolonged the lifespan in patients who suffer from 
these diseases.1 Horse ATG is being evaluated as a reliable first line therapy for patients with 
bone marrow failure disorders who do not have matched bone marrow or stem cell donors. 
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OBJECTIVE 
 The objective of this selective Evidence Based Medicine review is to determine whether 
or not Horse Antithymocyte Globulin (ATG) plus Cyclosporine (CsA) is the most effective first-
line therapy for patients with bone marrow failure disorders. 
METHODS 
 The criteria for this selective Evidence Based Medicine review evaluates two randomized 
control trials and one single-center retrospective study, which were chosen based on population, 
intervention, comparison groups, and outcomes measured. The selected population of interest 
was patients with bone marrow failure disorders, specifically Aplastic Anemia and 
Myelodysplastic Syndrome. The intervention in these three studies was Horse Antithymocyte 
Globulin combined with Cyclosporine. The treatment group whom received the aforementioned 
intervention was compared to the experimental group who, based on the study, either received 
Rabbit Antithymocyte Globulin with Cyclosporine or Basic Supportive Care. The outcomes 
measured in each of these three studies was overall survival. One study also measured the 
outcome of failure free survival. 
  The following keywords were entered and searched on PubMed to uncover articles 
relevant to the clinical question that also included results consistent with patient oriented 
outcomes. All articles were published in English between 2010 and 2013 in peer reviewed 
journals. The inclusion criteria was as follows: at least two randomized control trials containing 
patients with a diagnosis of either Aplastic Anemia or MDS published during or after the year 
2010. The exclusion criteria were any of the aforementioned patients who had received prior 
immunosuppressive therapies or who had severe comorbid conditions. The statistics used and 
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reported in this study were p-values, numbers needed to treat (NNT), and confidence intervals 
(CI).  
Table 1 – Demographics and Characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion criteria Exclusion criteria W/D Interventions 
Scheinberg4 
(2011) 
RCT 120 2-77 
years 
of 
age 
-Aplastic Anemia 
with bone marrow 
cellularity <30%, 
plus two of the 
following: 
absolute neutrophil 
count less than 
500, platelet count 
less than 20,000, 
absolute 
reticulocyte count 
less than 60,000 
-Age > 2 years 
-Weight > 12 kg 
-Fanconi’s anemia 
diagnosis, evidence 
of clonal disorder or 
cytogenetics, prior 
immunosuppressive 
therapy, infection, 
HIV, severe 
comorbid 
conditions, cancer 
patients currently 
undergoing 
chemotherapy, 
pregnancy, 
language barrier 
Not 
noted 
Horse ATG 40 
mg/kg of body 
weight/day x 4 
days plus 
Cyclosporine 
10 mg/kg/day 
x 6 months 
Passweg5 
(2010) 
RCT 88 > 18 
years 
-MDS diagnosis, -
Refractory anemia 
with or without 
sideroblasts or 
with excess blasts 
-Transfusion 
dependence for 
less than 24 
months 
-Age > 18 years 
-Eastern 
Cooperative 
Oncology Group 
performance status 
> 2 
-Patients with 
chronic 
myelomonocytic 
leukemia, refractory 
anemia with 
excessive blasts in 
transformation, 
secondary MDS, or 
infection 
5 Horse ATG 15 
mg/kg x 5 
days and oral 
Cyclosporine 
(CsA) x 180 
days 
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Shin6 
(2013) 
Single 
center 
retrospe
-ctive 
study 
99 > 15 
years  
-Adults with 
Severe Aplastic 
Anemia who 
received first-line 
therapy with horse 
ATG or rabbit 
ATG at Seoul St. 
Mary’s Hospital 
between February 
2001 and May 
2010 
-Prior 
immunosuppressive 
therapy, bone 
marrow findings 
consistent with 
MDS, or <15 years 
of age 
Not 
noted 
Horse ATG 15 
mg/kg/day x 5 
days plus 
Cyclosporine 
5-6 mg/kg/day 
x as long as 
patient was 
responding nor 
developing 
renal 
complications  
 
OUTCOMES MEASURED 
The outcomes in this selective Evidence-Based Medicine review are reported as patient-
oriented outcomes. The outcomes include overall survival, which was measured at different year 
markings post ATG therapy depending on the study, and failure free survival measured 5 years 
after ATG treatment.  
The Scheinberg et al randomized control trial measured overall survival at 3 years in 
Aplastic Anemia patients who received Horse ATG with CsA compared with overall survival at 
3 years in those Aplastic Anemia patients who had received Rabbit ATG with CsA. Overall 
survival at 3 years was determined using the Kaplan Meier curve which recorded the patients’ 
hematologic response at 6 months after treatment in both groups.4 
The Passweg et al randomized control trial measured overall survival at 2 years in low to 
intermediate risk myelodysplastic patients who received Horse ATG and CsA compared to the 
overall survival at 2 years of low to intermediate risk MDS patients who received basic 
supportive care.5  
The Shin et al single center retrospective study measured overall survival and failure free 
survival at 5 years in Severe Aplastic Anemia patients who received Horse ATG with CsA 
compared to the survival of those who received Rabbit ATG plus CsA. The Kaplan Meier curve 
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was for overall survival was used to determine the survival data by assessing complete 
hematologic response at 3, 6, 12, and 18 months after ATG therapy in both groups.6  
RESULTS  
 This selective evidence-based medicine review evaluates Horse Antithymocyte Globulin 
(ATG) with Cyclosporine as a first line treatment for patients with bone marrow failure 
disorders. The results of these studies were presented in dichotomous data. Two of these studies 
were randomized control trials while one was a single-center retrospective study.4,5,6  
 Scheinberg et al4 is a randomized control trial which assessed the efficacy of Horse ATG 
and CsA compared to Rabbit ATG and CsA in patients 2 years or older with treatment-naive 
Aplastic Anemia. This study encompassed 120 participants divided evenly into 60 patients per 
arm: 60 patients would receive Horse ATG and CsA (the treatment group) while the remaining 
60 would receive Rabbit ATG and CsA. This study presented a variety of outcomes, but this 
evidence based medicine review will focus on the patient oriented outcome of overall survival. 
Survival was measured at 3 years post-ATG therapy using the Kaplan Meier curve for overall 
survival. The Kaplan Meier curve data was determined based on hematologic response at 6 
months after ATG therapy in both groups. The extent of hematologic response was determined 
based on the return of blood counts to within normal ranges and having patients become 
transfusion-independent. Overall survival at 3 years significantly differed between the two 
treatment regimens as is evident from their respective confidence intervals: 96% of patients 
survived in the Horse ATG and CsA group whilst only 76% of patients survived in the Rabbit 
ATG and CsA group. As calculated by the results of the study, for every 5 patients receiving 
horse ATG plus CsA, 1 more patient is going to survive than if Rabbit ATG plus CsA was given 
initially (refer to Table 2 for NNT value). The difference between the two groups was 
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represented with a p-value of 0.04, making the data reported in this study statistically significant, 
and Horse ATG plus CsA the superior treatment option.  
Table 2: Clinical Efficacy of Using Horse ATG plus CsA to treat Aplastic Anemia 
Study CER (rATG) EER (hATG) RBI ABI NNT 
Scheinberg et 
al 
76% 96% 26.3% 20% 5 
CER – control event rate; EER – experimental event rate; RBI – relative benefit increase; ABI – absolute benefit increase; rATG 
– rabbit ATG; hATG – horse ATG 
 
Passweg et al5 is a randomized control trial which assessed the efficacy of Horse ATG 
and CsA compared to Basic Supportive Care (BSC) in patients older than eighteen years of age 
with a documented MDS diagnosis. This study encompassed 88 participants, 45 of which were 
randomly assigned to receive Horse ATG and CsA while the remaining 43 were randomly 
assigned to receive BSC. In this study, patients were permitted to cross over from the BSC group 
to the Horse ATG and CsA group if their MDS progressed to a more advanced stage or if they 
did not have a response with BSC after 6 months. This study qualified as a randomized control 
trial because patients were randomly assigned to their respective treatment arms. The patient 
oriented outcome measured in this study was overall survival, defined as “the time from trial 
registration until death as a result of any cause.”2 Overall survival was measured 2 years after 
treatment was administered. There was not much variability in the confidence intervals of overall 
survival for the respective treatment groups, as a total of 40 deaths had occurred throughout the 
study: 49% of the patients in the Horse ATG and CsA arm had survived, while 63% of the 
patients in the BSC arm had survived. The difference between the two groups was represented 
with a p-value of 0.828. As calculated by the results of the study, for every 7 patients receiving 
horse ATG plus CsA, 1 fewer patient is going to survive than if BSC was given initially (refer to 
Table 3 for NNT value).  Thus, based on the p-value and confidence intervals reported in this 
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study, there is no statistically significant difference between the use of Horse ATG plus CsA or 
BSC in MDS patients as it pertains to 2-year survival.  
Table 3: Clinical Efficacy of Using Horse ATG plus CsA to treat patients with MDS 
Study CER (BSC) EER (hATG) RBI ABI NNT 
Passweg et al 63% 49% -22.2% -14% -7 
 
Shin et al6 is a single-center retrospective study which assessed the efficacy of Horse 
ATG and CsA compared to Rabbit ATG and CsA in patients older than 15 years who received 
Horse or Rabbit ATG as a first-line therapy for Aplastic Anemia. This study retrospectively 
analyzed 99 participants, 46 of which were treated with Horse ATG plus CsA, while the 
remaining 53 were treated with Rabbit ATG plus CsA. There were two patient-oriented 
outcomes presented in the results including overall survival and failure free survival. Both of the 
survival data was measured at 5 years post-ATG therapy using the Kaplan Meier curve for 
overall survival. The Kaplan Meier curve data was determined based on the patient’s overall 
complete hematologic response at 3, 6, 12, and 18 months after ATG therapy in both groups. The 
extent of hematologic response was determined based on the return of blood counts to within 
normal ranges and having patients become transfusion-independent. Overall survival and failure 
free survival at 5 years did not display a significant difference between the two groups, which is 
evident by the respective p-values: 0.460 for overall survival and 0.911 for failure free survival. 
As calculated by the results of the study, for every 125 patients who received horse ATG plus 
CsA, 1 more patient is going to survive overall than if Rabbit ATG plus CsA was given initially 
(refer to Table 4 for NNT value). With the outcome of failure free survival, for every 6 patients 
who received horse ATG plus CsA, 1 more patient will relapse or require additional systemic 
therapy than if rabbit ATG plus CsA was given initially. Therefore, there is no statistically 
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significant difference between the use of Horse ATG plus CsA or Rabbit ATG plus CsA in 
Aplastic Anemia patients as it pertains to 5-year overall and failure free survival. 
Table 4: Retrospective Clinical Analysis of Using Horse ATG plus CsA to treat patients with 
Aplastic Anemia – Overall Survival and Failure Free Survival  
 CER (rATG) EER (hATG) RBI ABI NNT 
Overall 
Survival 
82.7% 83.5% 0.967% 0.8% 125 
Failure Free 
Survival 
40.9% 26.1% -36.2% -14.8% -6 
 
DISCUSSION 
 Antithymocyte globulin (ATG) is a polyclonal immunoglobulin in which the antibodies 
react with multiple T cell markers and other tissue antigens in order to induce 
immunosuppression.5,7 It is believed that ATG works by decreasing the circulating T cells while 
simultaneously regulating T cell activation.2 ATG is also very commonly used in combination 
with other immunosuppressive agents, such as Cyclosporine, in order to increase its efficacy 
(livertox). ATG is manufactured from the plasma of rabbits or horses which is then immunized 
with human T cells. Both Horse and Rabbit ATG are FDA approved2 and commercially available 
for use in the United States. ATG has been approved for use as an anti-rejection agent in solid 
organ transplantation and as immunosuppressive therapy for Aplastic Anemia. There are also a 
number off-label uses for ATG therapy,7 including its use in low to intermediate risk MDS 
patients.5 When first administered, ATG can cause multiple side effects due to a variety of 
reasons: the patient’s underlying condition, a foreign body immune response due to the animal 
product component, or initial T cell encounter with the ATG antibodies within the first few days 
of therapy. Side effects include serum sickness, anaphylaxis, high fever, dyspnea, nausea, chest 
pain, and diarrhea.7 
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While this selective Evidence Based Medicine review addresses the broader question of 
whether or not Horse ATG is the best initial therapy for patients with bone marrow failure 
disorders, the three studies included in this review actually address a further dimension to this 
question: ATG therapy as initial treatment for patients who do not qualify for bone marrow or 
stem cell transplantation. Each of the three studies displayed some evidence supporting ATG as a 
first line therapy for patients who do not initially qualify for transplantation at the time of 
diagnosis. Passweg et al reports that “stem cell transplantation is the only curative approach, but 
is not feasible for most patients.”5 Therefore, this paper is reviewing the secondary treatment 
option of Horse ATG plus CsA to transplantation for this patient population as another 
potentially curative approach.  
Although the data reported in each of the three studies demonstrated a varying degree of 
statistical significance, there were small discrepancies which could have ultimately impacted the 
results. In the Passweg et al5 study, one major limitation was the lack of an active comparator. 
With an active comparator, the study was only able to establish that Horse ATG plus CsA was 
better than no treatment at all, despite there being other immunosuppressive treatments available. 
Another limitation, present in all of the involved studies, was the relatively small patient 
population. However, the rarity of these diseases would make it rather difficult to conduct a 
traditional large-scale study. 
CONCLUSION 
 Scheinberg et al4 was the only one of the three studies presented in this selective 
Evidence Based Medicine review that successfully supported the ultimate question. It 
demonstrated that Horse ATG was, in fact, the superior immunosuppressive treatment of choice 
for patients with bone marrow failure disorders who did not qualify for transplantation at the 
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time of diagnosis. The remaining two articles provided inconclusive data regarding overall 
survival where the depicted p-values represented insignificant results between Horse ATG plus 
CsA compared to another treatment modality, including BSC and Rabbit ATG plus CsA.5,6 Due 
to the inconsistency with data across the spectrum of these studies, further research would be 
warranted to determine the initial immunosuppressive treatment of choice for patients with bone 
marrow failure disorders who do not qualify for transplantation. In the future, it would also be 
useful to create a study which compares the initial and superior immunosuppressive treatment to 
transplantation in order to assess the overall efficacies of both treatment modalities. Therefore, 
patients could ultimately benefit by weighing the benefits and risks of each treatment option. 
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